Paper39339232
Exploring the Therapeutic Implications of Co-Targeting the EGFR and Spindle Assembly Checkpoint Pathways in Oral Cancer.
Calheiros-Lobo M and 5 others. Pharmaceutics, 2024. Cited by 4 papers, by iCite.
Cite this record
ConductScience Library. Exploring the Therapeutic Implications of Co-Targeting the EGFR and Spindle Assembly Checkpoint Pathways in Oral Cancer. Papers, record 39339232. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39339232
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Exploring the Therapeutic Implications of Co-Targeting the EGFR and Spindle Assembly Checkpoint Pathways in Oral Cancer.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants6
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| AntiMitoSphere_APSFCT_IINFACTS_2021 | Cooperativa de Ensino Superior Politécnico e Universitário Crl (CESPU) | PubMed | ||
| Flav4Tumor-GI2-CESPU- 2022 | Cooperativa de Ensino Superior Politécnico e Universitário Crl (CESPU) | PubMed | ||
| SGA4Cancer-GI2-CESPU-2022 | Cooperativa de Ensino Superior Politécnico e Universitário Crl (CESPU) | PubMed | ||
| upPTXovcar-GI2-CESPU-2022 | Cooperativa de Ensino Superior Politécnico e Universitário Crl (CESPU) | PubMed | ||
| BeatCancer-GI2-CESPU-2023 | Cooperativa de Ensino Superior Politécnico e Universitário Crl (CESPU) | PubMed | ||
| BD/CBAS/CESPU/01/2021 | Cooperativa de Ensino Superior Politécnico e Universitário Crl (CESPU) | PubMed |
Source PubMed
References245
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 25937431 | Pharmacokinetic assessment of dacomitinib (pan-HER tyrosine kinase inhibitor) in patients with locally advanced head and neck squamous cell carcinoma (LA SCCHN) following administration through a gastrostomy feeding tube (GT). | Invest New Drugs | 2015 | https://conductscience.org/library/papers/25937431 | PubMed |
| 2 | 24496920 | Phase I study of weekly nab-paclitaxel + weekly cetuximab + intensity-modulated radiation therapy (IMRT) in patients with stage III-IVB head and neck squamous cell carcinoma (HNSCC). | Ann Oncol | 2014 | https://conductscience.org/library/papers/24496920 | PubMed |
| 3 | 26418897 | The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer. | Oncotarget | 2015 | https://conductscience.org/library/papers/26418897 | PubMed |
| 4 | 20498391 | Epidermal growth factor receptor inhibitor gefitinib added to chemoradiotherapy in locally advanced head and neck cancer. | J Clin Oncol | 2010 | https://conductscience.org/library/papers/20498391 | PubMed |
| 5 | 26205191 | EGFR targeted therapies and radiation: Optimizing efficacy by appropriate drug scheduling and patient selection. | Pharmacol Ther | 2015 | https://conductscience.org/library/papers/26205191 | PubMed |
| 6 | 30370340 | Phase II study of induction chemotherapy with docetaxel, cisplatin, 5-fluorouracil followed by radioimmunotherapy with cetuximab and intensity-modulated radiotherapy in combination with a carbon ion boost for locally advanced tumors of the oro-, hypopharynx and larynx. | Clin Transl Radiat Oncol | 2018 | https://conductscience.org/library/papers/30370340 | PubMed |
| 7 | 33465681 | Palbociclib and cetuximab in cetuximab-resistant human papillomavirus-related oropharynx squamous-cell carcinoma: A multicenter phase 2 trial. | Oral Oncol | 2021 | https://conductscience.org/library/papers/33465681 | PubMed |
| 8 | 28029303 | E1308: Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx- ECOG-ACRIN Cancer Research Group. | J Clin Oncol | 2017 | https://conductscience.org/library/papers/28029303 | PubMed |
| 9 | 33114379 | Randomized Phase II Study with Cetuximab in Combination with 5-FU and Cisplatin or Carboplatin vs. Cetuximab in Combination with Paclitaxel and Carboplatin for Treatment of Patients with Relapsed or Metastatic Squamous Cell Carcinoma of the Head and Neck (CETMET Trial). | Cancers (Basel) | 2020 | https://conductscience.org/library/papers/33114379 | PubMed |
| 10 | 15238978 | Targeting the epidermal growth factor receptor. | Br J Cancer | 2004 | https://conductscience.org/library/papers/15238978 | PubMed |
| 11 | 37161880 | Characteristics of oral squamous cell carcinoma focusing on cases unaffected by smoking and drinking: A multicenter retrospective study. | Head Neck | 2023 | https://conductscience.org/library/papers/37161880 | PubMed |
| 12 | 27192495 | The Keap1-Nrf2-ARE Pathway As a Potential Preventive and Therapeutic Target: An Update. | Med Res Rev | 2016 | https://conductscience.org/library/papers/27192495 | PubMed |
| 13 | 34528763 | A phase II study of poziotinib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. | Cancer Med | 2021 | https://conductscience.org/library/papers/34528763 | PubMed |
| 14 | 31575759 | High Proliferation Rate and a Compromised Spindle Assembly Checkpoint Confers Sensitivity to the MPS1 Inhibitor BOS172722 in Triple-Negative Breast Cancers. | Mol Cancer Ther | 2019 | https://conductscience.org/library/papers/31575759 | PubMed |
| 15 | 24406211 | The role of reactive oxygen species and metabolism on cancer cells and their microenvironment. | Semin Cancer Biol | 2014 | https://conductscience.org/library/papers/24406211 | PubMed |
| 16 | 24677053 | Transphosphorylation of EGFR at Y845 plays an important role in its autophosphorylation and kinase activity. | Oncol Rep | 2014 | https://conductscience.org/library/papers/24677053 | PubMed |
| 17 | 29355614 | Head and neck squamous cell carcinoma: Genomics and emerging biomarkers for immunomodulatory cancer treatments. | Semin Cancer Biol | 2018 | https://conductscience.org/library/papers/29355614 | PubMed |
| 18 | 23041591 | Adjuvant therapy with cetuximab for locally advanced squamous cell carcinoma of the oropharynx: results from a randomized, phase II prospective trial. | Ann Oncol | 2013 | https://conductscience.org/library/papers/23041591 | PubMed |
| 19 | 23460709 | Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trial. | J Clin Oncol | 2013 | https://conductscience.org/library/papers/23460709 | PubMed |
| 20 | 21952273 | Combined modality treatment with chemotherapy, radiation therapy, bevacizumab, and erlotinib in patients with locally advanced squamous carcinoma of the head and neck: a phase II trial of the Sarah Cannon oncology research consortium. | Cancer J | 2011 | https://conductscience.org/library/papers/21952273 | PubMed |
Cited by2
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 4 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42432132 | Comprehensive multi-omic dissection and AI-prioritized target identification in inverted papilloma-associated sinonasal squamous cell carcinoma. | NPJ Precis Oncol | 2026 | https://conductscience.org/library/papers/42432132 | PubMed |
| 40133563 | Exploring cell death pathways in oral cancer: mechanisms, therapeutic strategies, and future perspectives. | Discov Oncol | 2025 | https://conductscience.org/library/papers/40133563 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| EGFR | 1956 | PubTator's text mining | https://conductscience.org/library/genes/1956 | NCBI Gene |
| TTK | 7272 | PubTator's text mining | https://conductscience.org/library/genes/7272 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39339232
GET https://conductscience.org/api/papers/v1/39339232/references?page=2